Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 862 matching trials from the live ClinicalTrials.gov search.
Conditions
Non-small Cell Lung Cancer, Breast Cancer, Prostate Cancer
Interventions
imexon, docetaxel
Drug
Lead sponsor
AmpliMed Corporation
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Houston, Texas
Conditions
Cancer, Solid Tumor Cancer, Advanced Metastatic Cancer, Prostate, Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer
Interventions
SYS6043
Drug
Lead sponsor
Conjupro Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
5
States / cities
Plantation, Florida • Austin, Texas • San Antonio, Texas + 1 more
Conditions
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Interventions
Enzalutamide
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
Male only
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
9
States / cities
Anchorage, Alaska • Detroit, Michigan • New York, New York + 5 more
Conditions
Advanced Solid Tumor, Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
Interventions
Elimusertib (BAY1895344)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
14
States / cities
Duarte, California • Tampa, Florida • Atlanta, Georgia + 10 more
Conditions
Prostatic Neoplasms, Castration-Resistant
Interventions
JNJ-64041809 (Cohort 1A and 1B), JNJ-64041809 (Cohort 2A and 2B)
Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
6
States / cities
San Francisco, California • Baltimore, Maryland • St Louis, Missouri + 3 more
Conditions
Prostate Cancer Metastatic
Interventions
Opevesostat, Abiraterone acetate, Enzalutamide, Hydrocortisone, Fludrocortisone acetate, Prednisone, Dexamethasone
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
48
States / cities
Orange, California • Palo Alto, California • Riverside, California + 41 more
Conditions
Prostate Cancer Metastatic
Interventions
EMD 525797, Placebo, Standard of Care (SoC)
Drug · Other
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older · Male only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
12
States / cities
Pleasant Hill, California • Chicago, Illinois • New Orleans, Louisiana + 9 more
Terminated Phase 1Phase 2 Interventional Results available

RNActive®-Derived Therapeutic Vaccine

NCT00906243
Conditions
Hormone Refractory Prostate Cancer
Interventions
CV9103
Biological
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) V8
Interventions
Cyclophosphamide, Dexamethasone
Drug
Lead sponsor
Rashmi Verma, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Sacramento, California
Conditions
Prostate Cancer
Interventions
TAK-700
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Ann Arbor, Michigan • Portland, Oregon • Madison, Wisconsin
Conditions
Prostatic Neoplasms, Castration-Resistant
Interventions
64Cu-SAR-bisPSMA, 67Cu-SAR-bisPSMA
Drug
Lead sponsor
Clarity Pharmaceuticals Ltd
Industry
Eligibility
18 Years and older · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Stanford, California • River Ridge, Louisiana • Grand Rapids, Michigan + 4 more
Conditions
Prostate Cancer
Interventions
Pacritinib
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Prostate Cancer, Castration Resistant Prostate Cancer
Interventions
Enzalutamide, CC-115
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
5
States / cities
San Francisco, California • Baltimore, Maryland • New York, New York + 2 more
Conditions
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Interventions
GT0918
Drug
Lead sponsor
Suzhou Kintor Pharmaceutical Inc,
Industry
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
6
States / cities
Towson, Maryland • Omaha, Nebraska • Las Vegas, Nevada + 3 more
Conditions
Metastatic Prostate Cancer
Interventions
AZD0754, AZD2287
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
13
States / cities
Duarte, California • Tampa, Florida • Atlanta, Georgia + 8 more
Conditions
Prostate Cancer
Interventions
ARRx, Enzalutamide
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Ann Arbor, Michigan • Detroit, Michigan
Conditions
Prostate Cancer
Interventions
Immunotherapy allogeneic GM-CSF secreting cellular vaccine
Biological
Lead sponsor
Cell Genesys
Industry
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
12
States / cities
Laguna Woods, California • San Francisco, California • Tarzana, California + 8 more
Conditions
Prostatic Neoplasms
Interventions
Abemaciclib, Darolutamide, LHRH agonist/antagonist
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Springdale, Arkansas • Mineola, New York • New York, New York
Conditions
Prostate Cancer
Interventions
tasquinimod, Placebo
Drug
Lead sponsor
Active Biotech AB
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
34
States / cities
Tucson, Arizona • Oxnard, California • Santa Monica, California + 31 more
Conditions
Bone Metastatic Castration-Resistant Prostate Cancer
Interventions
Biomarker analysis, Administration of radium-223
Device · Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Prostate Cancer
Interventions
Nilutamide, Dasatinib
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
3
States / cities
Durham, North Carolina • Portland, Oregon • Seattle, Washington
Completed Phase 2 Interventional Results available

AMG 386 and Abiraterone for Advanced Prostate Cancer

NCT01553188
Conditions
Prostatic Neoplasms, Prostate Cancer, Neoplasm, Prostate, Neoplasm,Prostatic
Interventions
AMG 386, Abiraterone, Prednisone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
2
States / cities
Bethesda, Maryland • Philadelphia, Pennsylvania
Conditions
Cancer, Prostate
Interventions
Mitoxantrone, Siltuximab, Prednisone
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
11
States / cities
Norwalk, Connecticut • Port Saint Lucie, Florida • Atlanta, Georgia + 8 more
Conditions
Prostate Cancer Metastatic
Interventions
Apalutamide, Abiraterone acetate, Docetaxel, Prednisone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
2
States / cities
Omaha, Nebraska • New York, New York